OrganOx

OrganOx, founded in 2008 as a spin-out from the University of Oxford, has established itself as a global leader in the field of organ transplantation technology. The company's flagship product, the OrganOx metra, is a fully automated, transportable perfusion system that preserves donor livers in a near-physiological state for up to 24 hours prior to transplantation. By continuously perfusing the organ with oxygenated blood, nutrients, and medications at normal body temperature, the metra mimics the conditions of the human body, allowing for real-time functional assessment and significantly reducing the risk of early graft dysfunction. This innovation addresses one of the most critical challenges in transplantation: the limited viability window of donor organs, which often leads to the unnecessary discard of otherwise healthy livers.

OrganOx’s technology has been adopted by leading transplant centers across Europe, North America, and beyond, with more than 4,000 liver transplants supported globally. The company’s approach not only extends the preservation time for donor organs but also empowers clinicians with live data to make evidence-based decisions, improving patient outcomes and optimizing the use of scarce donor resources. OrganOx continues to expand its impact, with ongoing research and development aimed at applying its perfusion platform to other organs, such as kidneys, and advancing the science of organ preservation. The company’s commitment to innovation, supported by substantial investment and a state-of-the-art research facility in Oxford, positions it at the forefront of medical device technology, offering hope and improved quality of life to thousands of patients suffering from organ failure